We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Use of Mobile Teledermatology in the Care of Acne Patients (Teleacne)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01399970
Recruitment Status : Completed
First Posted : July 22, 2011
Last Update Posted : January 14, 2014
National Bank of Austria
Information provided by (Responsible Party):
Rainer Hofmann-Wellenhof, MD, Medical University of Graz

Brief Summary:

The purpose of the present study is to determine whether a mobile teledermatology care model can achieve better clinical outcomes as compared to conventional, outpatient care for the management of severe acne treated with isotretinoin.

The superiority of mobile care in comparison to conventional, outpatient care will be investigated regarding

  1. effectiveness: Global evaluation Acne (GEA) score -response at week 24
  2. safety: drop out rates and medication side effects
  3. overall patient satisfaction with acne care and therapy
  4. overall physician satisfaction with mobile acne care

Condition or disease Intervention/treatment
Acne Other: Mobile Teleconsultation Arm (MTA) Other: Outpatient Consultation Arm (OCA)

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 69 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Health Services Research
Official Title: Use of Mobile Teledermatology in the Care of Acne Patients - A Randomized Controlled Trial
Study Start Date : April 2011
Primary Completion Date : December 2012
Study Completion Date : January 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Acne
U.S. FDA Resources

Arm Intervention/treatment
Outpatient Consultation Arm (OCA)
Conventional in Office Care
Other: Outpatient Consultation Arm (OCA)
Patients will receive routine outpatient care at the clinic according to the treatment guidelines, and will be scheduled for outpatient visits every 4 weeks.
Other Names:
  • OCA
  • Health Care Service Modality
Experimental: Mobile Teleconsultation Arm (MTA)
Mobile Teledermatology Care
Other: Mobile Teleconsultation Arm (MTA)
In addition to a face-to-face visit at baseline, patients will conduct "mobile visits" at home every two weeks. The general practitioner of choice will perform examinations, such as laboratory or occasionally pregnancy tests every 4 weeks according to the treatment guidelines.
Other Names:
  • MTA
  • Health Care Service Modality

Primary Outcome Measures :
  1. Global evaluation Acne score (GEA) [ Time Frame: week 24 ]
    Change from Baseline in the median GEA score at week 24

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   12 Years to 30 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Female or male, aged 12 to 30 years

  • with facial acne
  • requiring systemic isotretinoin treatment (GEA-Score: 3-5)
  • with basic handy skills
  • with a signed consent form

Exclusion Criteria:

  • Pregnancy or lactation period
  • Withdrawal of informed consent
  • Non-compliance, failure to comply with protocol requirements

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01399970

Department of Dermatology, Medical University of Graz
Graz, Austria, 8036
Sponsors and Collaborators
Medical University of Graz
National Bank of Austria
Study Director: Rainer Hofmann-Wellenhof, MD Department of Dermatology, Medical University of Graz

Responsible Party: Rainer Hofmann-Wellenhof, MD, Prof. Dr., Medical University of Graz
ClinicalTrials.gov Identifier: NCT01399970     History of Changes
Other Study ID Numbers: 02
First Posted: July 22, 2011    Key Record Dates
Last Update Posted: January 14, 2014
Last Verified: January 2014

Keywords provided by Rainer Hofmann-Wellenhof, MD, Medical University of Graz:
Mobile Teledermatology